Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2931487 | 0.86 | TSHR (0.59) | PIK3CDTSHRADRA1DADRA1AADRA1B | |
| SCHEMBL14048407 | 0.81 | TSHR (0.50) | PIK3CDTSHRADRA1DADRA1AADRA1B | |
| SCHEMBL668453 | 0.80 | TSHR (0.56) | PIK3CDTSHRADRA1DADRA1AADRA1B | |
| SCHEMBL15061933 | 0.78 | TSHR (0.54) | PIK3CDTSHRADRA1DADRA1AADRA1B | |
| SCHEMBL31632746 | 0.78 | GAA (0.48) | TSHRADRA1DADRA1AADRA1BLMNA | |
| SCHEMBL31632742 | 0.78 | GAA (0.48) | TSHRADRA1DADRA1AADRA1BLMNA | |
| SCHEMBL31632714 | 0.78 | GAA (0.48) | TSHRADRA1DADRA1AADRA1BLMNA | |
| SCHEMBL31632755 | 0.78 | GAA (0.48) | TSHRADRA1DADRA1AADRA1BLMNA | |
| SCHEMBL13622261 | 0.78 | GAA (0.48) | TSHRADRA1DADRA1AADRA1BLMNA | |
| SCHEMBL13622262 | 0.78 | GAA (0.48) | TSHRADRA1DADRA1AADRA1BLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090285868-A1 | Photostable cosmetic compositions comprising dibenzoylmethane/pyrrolidinone compounds | L'OREAL (FR) | 2009-11-19 | — | — | US | disclosed |
| US-20090285868-A1 | Photostable cosmetic compositions comprising dibenzoylmethane/pyrrolidinone compounds | L'OREAL (FR) | 2009-11-19 | — | — | US | disclosed |
| EP-2119429-A1 | Cosmetic composition containing a dibenzoylmethane derivative and a pyrrolidinone derivative; method for photostabilising the dibenzoylmethane derivative | L'Oréal (FR) | 2009-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090285868-A1 | Photostable cosmetic compositions comprising dibenzoylmethane/pyrrolidinone compounds | NOTUM, CYP51A1, DHPS | PIK3CD 2030/4885TSHR 4230/4885ADRA1D 4350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.